INTRODUCTION
Despite successful implementation of imatinib and secondgeneration tyrosine kinase inhibitors (TKIs) as first-line therapies for chronic myelogenous leukemia (CML) in chronic phase (CML-CP), the majority of blast crisis CML (CML-BC) and Philadelphiapositive (Ph þ ) B-cell acute lymphoblastic leukemia (B-ALL) patients do not show long-term responses to TKIs or any other therapeutic option. [1] [2] [3] [4] [5] [6] The molecular mechanisms responsible for blastic transformation and drug resistance in CML-BC are still unclear but likely involve both BCR-ABL1 kinase-dependent andindependent mechanisms. 4 Presence of BCR-ABL1 mutations can only, in part, explain the development of TKI resistance; 7 in fact, both cell autonomous (for example, enhanced Src and LYN kinase activity) 8 and microenvironment-induced signals 9, 10 contribute to development of drug resistance and increased survival of CD34 þ CML-BC progenitors. 4 The latter seems to depend, at least in part, on increased levels and/or activity of antiapoptotic Bcl-2, 11 Bcl-xL 9, 12, 13 and Mcl-1. 9, 14, 15 Although Mcl-1, but not Bcl-2, is essential for survival of normal and Ph þ leukemic stem cell (LSC) populations, [16] [17] [18] [19] the role of Bcl-xL in their maintenance in vivo is still unknown. Although loss of Bcl-xL by itself or its pharmacological antagonism in combination with that of Bcl-2 in B-ALL mouse models did not dramatically improve survival, [20] [21] [22] exposure of TKI-resistant CML-BC stem and progenitor cells to the Bcl-xL/Bcl-2 antagonist ABT-737 induced apoptosis by partially restoring sensitivity to imatinib. 23 However, therapeutic CML-BC strategies involving pharmacological antagonism of Bcl-xL could be further refined and potentiated not only by associating a BclxL/Bcl-2 antagonist with TKIs, as BCR-ABL1 kinase mutationindependent relapse is the common outcome for TKI-treated CML-BC patients, 24 but also by combining the orally bioavailable formulation of ABT-737 (that is, ABT-263) that reportedly has a clinically manageable toxicity profile, 25 with other non-toxic drugs capable of further modulating apoptosis. As the BCR-ABL1-regulated [26] [27] [28] pro-apoptotic factor BAD is the primary binding partner of Bcl-xL, 25 and it undergoes phosphorylation (inhibition) upon cytokine-or oncogene-induced activation of Akt and mTORC1/2 (mammalian target of rapamycin complex 1/2) signaling, 29 pharmacological restoration of BAD activity combined with suppression of Bcl-xL activity might fully restore TKI sensitivity or, per se, strongly initiate apoptosis of CML-BC progenitors even when BCR-ABL kinase-independent signals (for example, microenvironmental-induced 9, 10 ) control survival of CML-BC progenitors. Thus, it is highly plausible that dual inhibitors of the BCR-ABL1-activated 30, 31 and PI3K-Aktdependent mTORC complexes1/2 29 (for example, OSI-027 32 and PP242 33 ), which reportedly limit proliferation and colony-forming ability of mononuclear cells (MNCs) from CML-BC patients, have the strong ability to activate BAD and likely potentiate the effects of Bcl-xL/Bcl-2 antagonism in CML-BC.
Here we show that deletion of the bcl-x gene in the BCR-ABL1
þ LSC-enriched cell compartment neither altered stem cell frequency nor improved mice survival; albeit none of the bcl-xdeficient mice underwent disease progression and developed a lymphoid CML-BC-like leukemia phenotype, 36 suggesting that BclxL may be important for the survival of BCR-ABL1 þ progenitors undergoing progression. Additionally, we found that PP242 has the ability to activate BAD and potentiate the effects of ABT-263-mediated antagonism of Bcl-xL. Combination of ABT-263 with PP242 efficiently and selectively induced apoptosis in BCR-ABL1 þ cell lines and primary CML-BC progenitors, but not CD34 þ progenitors from healthy donors, and overcame TKI resistance induced by signals generated by stromal cells. Furthermore, shRNA studies confirmed that efficacy of this strategy depends, at least in part, on PP242-induced BAD activation. Likewise, genetic manipulation of the BCR-ABL1/Bcl-xL/BAD interplay through shRNA-mediated impairment of the BCR-ABL1-regulated heterogeneous ribonuclear protein A1 (hnRNP A1) 37 resulted in lower levels of Bcl-xL expression and BCR-ABL1 kinase activity and increased sensitivity of CD34 þ CML-BC progenitors to the pro-apoptotic activity of PP242, suggesting that the efficacy of ABT-263 in these studies results from its ability to inhibit Bcl-xL and not Bcl2. Furthermore, antagonism of Bcl-xL while activating BAD may represent an efficient pharmacological approach to augment TKI-based therapeutic protocols for CML patients with advanced and drug-insensitive stages of the disease.
MATERIALS AND METHODS
Generation and analysis of the Bcl-xL-deficient BCR-ABL þ transgenic mice Inducible SCLtTA-BCR-ABL1-cre-bcl-x fl/fl mice were generated through cross breeding of SCLtTA, 36 pTRE-BCR-ABL1 38 and tet-O-cre 39 lines, with mice carrying loxP sites flanking exons 1 and 2 of the bcl-x gene. 40 Breeding was done while administering tetracycline in drinking water; 38 PCR-mediated genotyping was performed as described 38 with genespecific primers (Table 1) . Efficiency of recombination within bcl-x was assessed by 3-primer (A, B and C) PCR 40 on DNA isolated from bone marrow (BM) and splenic MNCs. Following recombination, primers A and C generate the 280 base pair product (bp). In the presence of a nonrecombined allele, primers A and C do not amplify and the 300 bp product from primers A and B is observed. Induction of BCR-ABL1 (p210) transgene and cre recombinase was achieved by tetracycline withdrawal. þ /c-Kit þ (LSK) cells were isolated from femur and/ or spleen of induced and non-induced (wild type) animals as described. 36 All in vitro studies using primary mouse cells were done with the OSU IACUC's approval. Colony forming (colony-forming cells) and replating assays, determination of LTC-IC frequency and lentiviral production and transduction were performed as described in Supplementary Methods.
Isolation of stem/progenitor cell-enriched fractions and flow cytometry-based assays Total and lineage-depleted mouse BM cells were isolated as described. 36 fluorescent-activated cell sorter (FACS)-mediated analysis of hematopoietic markers was performed with combinations of the following antibodies: anti-Gr-1 PE, anti-Mac-1 FITC, anti-B220 APC, anti-CD19 PeCy7, anti-Ter119 PeCy7, anti-c-kit APC AF750 (eBioscience, San Diego, CA, USA), anti-CD71 Biotin and anti-Sca-1 PeCy7 (BD Biosciences, San Jose, CA, USA). CML specimens were subjected to CD34-positive selection, and the hematopoietic stem cell-enriched fraction (CD34 þ /CD38 À ) along with common myeloid progenitors (
were separated following staining with anti-CD34 AF647 (4H11), anti-CD38 PeCy7 (HIT2) (eBioscience), anti-CD123 PE (9F5) (BD Pharmingen, San Jose, CA, USA) and anti-CD45Ra PE Texas Red (Life Technologies, Grand Island, NY, USA) antibodies and cell sorting (Aria, Becton Dickinson, Franklin Lakes, NJ, USA). Determination of the percentage of apoptotic cells in untreated and after 3 (cell lines) and 6 (primary cells) days of drug treatment were assessed by Annexin V PE staining (BD Biosciences) and Sytox Blue Live/Dead Stain (Life Techonologies). All analyses were performed on a tri-laser FACS (LSRII, Becton Dickinson). Cells were thereafter used for RNA isolation, real-time PCR and western blot analyses as described in detail in Supplementary Methods.
Reagents (chemical inhibitors and plasmids)
Culture medium containing cell lines and primary cells seeded at a density of 10 5 and 10 6 per milliliter, respectively, were exposed to inhibitors at the doses indicated in the results section. Cell lines were treated for 72 h, except for LAMA84 cells, which were treated for 24 h owing to sensitivity to all the treatments. The drugs used include Imatinib (Novartis, East Hanover, NJ, USA), LY294002 (Cayman Chemical, Ann Arbor, MI), Rapamycin (Sigma, 0 -tAGCAAGAGATGGCTAGTGCttcaagagaGCACTAGCCATCTCTTGCTtttttggaac-3 0 into the HpaI and NotI sites of the pLL3.7 lentiviral plasmid. Bases specific for hnRNP A1 shRNA are capitalized. The BAD shRNA-containing lentiviral construct was generated as described. 42 
Statistical analysis
Data are expressed as means ± s.e.m. and were compared using the Student's t-test and/or Fisher exact tests. P-values p0.05 are considered significant.
RESULTS
The survival factor Bcl-xL is dispensable for development of CML in vivo BCR-ABL1-dependent induction of Bcl-xL expression, albeit not required for the emergence of Ph þ -ALL in animals, 22 seems to be important, at least in vitro, for the survival of CML-BC cell lines. 12, 13 High levels of BCR-ABL1 expression similar to those found in CML-BC blasts 43 resulted in the imatinib-sensitive induction of survival factors Mcl-1 and Bcl-xL, but not Bcl-2, and in increased expression and activity of their post-transcriptional modulators 37, 43, 44 (for example, hnRNP A1) and upstream regulators of cell survival (for example, Akt; Figure 1a , top left). Accordingly, Akt-regulated activity of pro-apoptotic BAD was restored upon kinase inhibition of BCR-ABL1, as indicated by the appearance of the nonphosphorylated (active 45 ) BAD in the mitochondrial fraction of imatinib-treated 32D-BCR-ABL1 cells ( Figure 1a , bottom left). To assess whether expression of Bcl-xL has a role in CML-development, maintenance and/or progression in vivo, we crossed SCLtTA-BCR-ABL1 (dTg) mice, which upon induction of BCR-ABL1 develop a CML-like myeloproliferative disorder that progresses into a lymphoid blast crisis (L-BC)-like disease in 30% of mice, 36 with inducible bcl-x-deficient animals 22 Figure S1B , left) and did not demonstrate significantly different overall survival (P ¼ 0.14; Figure 1d ), suggesting that the anti-apoptotic potential of Bcl-xL might be dispensable for both the maintenance of human Ph þ stem cell compartment and development of CML. In fact, succumbed dTg/KO mice had a phenotype mostly superimposable with that of the original SCLtTA-BCR-ABL1 mouse model. 36 In addition to splenomegaly and high percentages of Gr-1 þ /Mac-1 þ cells in PB, BM and spleen (Supplementary Figure S1A) , they also presented pale brittle bones (not shown) and massive infiltration of myeloid cells into spleen, liver and kidney (Supplementary Figure S1B, right) . Likewise, deletion of Bcl-x did not alter the frequency of erythroid (Ter119 Figure S1A) . Consistent with the existence of a BCR-ABL1-induced and hnRNP A1-mediated post-transcriptional control of Bcl-xL expression, 37 we found almost identical levels of bcl-x mRNA in wild-type and dTG LSK cells (Figure 1b Bcl-xL expression is required for CML disease progression in vivo To determine whether Bcl-xL has a role in CML blastic transformation, a cohort of 8-12-week-induced dTg (n ¼ 8) and dTg/KO (n ¼ 12) animals presenting with marked neutrophilia, as evidenced by the percentage of Gr-1 þ /Mac-1 þ cells almost twice that of non-induced littermates (%Gr-1 þ /Mac-1 þ : 24.05 ± 3.0 (dTg); 34.9 ± 3.8 (dTg/KO); and 13.6 ± 1.7 (non-induced control mice; n ¼ 3)), were monitored for signs of disease progression. 36 A significantly increased number of B220 þ /CD19 þ cells in PB (Figure 2a Inhibition of Bcl-xL triggers apoptosis of BCR-ABL1 þ myeloid progenitors and is potentiated by reactivation of BAD Previous studies report that it is the anti-apoptotic activity of Bcl-xL, but not Bcl-2, which reconstitutes most, albeit not entirely, the leukemogenic potential 4, 12, 46 of BCR-ABL1 in CML-BC-progenitors. To assess whether Bcl-xL can be used as a therapeutic target in CML-BC, 32D-BCR-ABL1 and LAMA84, which are models of BC, were used to assess sensitivity of these cells to the Bcl-xL/Bcl-2 antagonist ABT-263. In three independent experiments, flow cytometric analysis of Annexin V-and Sytox Blue-stained cells revealed that treatment with a single dose of ABT-263 (1 mM) induced a B50% decrease in cell survival compared with vehicle-treated cells (Figure 3a, left) . Furthermore, ABT-263 (1 mM) did not alter the percentage of dTg (n ¼ 4) LSK-derived colony-forming cells (B10% inhibition) and their replating efficiency (Figure 3a, middle) . Similarly, the LTC-IC frequency of Lin À BM cells from 8-weekinduced dTg mice (n ¼ 3) remained almost identical in untreated and ABT-263-treated cells (B15% reduction) (Figure 3a, right) , suggesting that loss of Bcl-xL does not influence the self-renewal and survival of BCR-ABL1-transformed hematopoietic stem cells.
Thus, because of the important role played by BAD in BCR-ABL1-driven leukemogenesis [26] [27] [28] [29] and in the regulation of Bcl-xL activity, 25 we evaluated whether pharmacological activation of BAD achieved through interference with the PI3K/Akt/mTORC1/2 29 or MEK1/MAPK 47 signaling enhances ABT-263-induced apoptosis of BCR-ABL1 þ cells. 32D-BCR-ABL1 cells were treated for 18 h with the archetypical PI3-kinase inhibitor LY294002 (20 mM), mTORC1 inhibitor Rapamycin (0.1 mM), mTORC1/2 inhibitor PP242 (0.1 mM) or the MAP-kinase inhibitor U0126 (25 mM), and the levels of phosphorylated (pBAD) and non-phosphorylated BAD as well as that of other survival signaling molecules (for example, Akt, Mcl-1, Bcl-xL, Bcl-2 and c-Myc) were determined. Western blot analysis performed on subcellular fractionated (Figure 3b , left) and total protein lysates (Figure 3b, right) show that PP242, LY294002 and Rapamycin induced BAD activation as indicated by the readily detectable non-phosphorylated BAD in whole cell and mitochondrial lysates (Figure 3b, left) . By contrast, inhibition of MEK1 by U0126 did not induce BAD activation (Figure 3b) , consistent with persistence of Akt-and p70 S6 kinase-dependent BAD phosphorylation on serine 136. 29 As expected, BAD was heavily phosphorylated/inactive in vehicletreated (untreated; Figure 3b , left) 32D-BCR-ABL1 cells. Likewise, levels of Mcl-1 and that of c-Myc were significantly reduced by treatment with LY294002, PP242 or Rapamycin, and PP242 or Rapamycin, respectively (Figure 3b, right) , while expression of BclxL and Bcl-2 were not influenced by suppression of PI3K/Akt/ mTORC1/2-mediated signals (Figure 3b, right) . Activation of BAD in PP42-treated 32D-BCR-ABL1 and LAMA84 cells did not alter survival ( Figure 3a) ; however, 90-95% were apoptotic (Annexin V þ ) after exposure of both BCR-ABL1 þ lines to single treatment with a combination of 1 mM ABT-263 and 0.2 mM PP242 (n ¼ 3) (Figure 3a, left) . Although previous work reported a modest decrease (MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)-based assay) in proliferation/ survival in PP242-treated BCR-ABL1 þ cell lines, 35 PP242 failed to induce apoptosis of both LAMA84 and 32D-BCR-ABL cells when used at lower concentrations (0.2 mM) (Figure 3a , top), most likely due to high Bcl-xL levels. The potentiating effect of this TORC1/2 inhibitor on the pro-apoptotic activity of ABT-263 in cell line models of BC may depend on its ability to activate BAD, which, in turn, antagonizes the anti-apoptotic function of Bcl-xL. 25 We tested this hypothesis by genetic manipulation of BAD expression with shRNA which showed that B50% BAD knockdown in K562 cells (Figure 3c 
The combination of ABT-263 with PP242 triggers apoptosis of CML-BC but not CML-CP or normal CD34
þ progenitor cells and overcomes microenvironment-induced TKI resistance Methylcellulose-based clonogenic assays revealed that the combination of ABT-263 (0.1 mM) and PP242 (0.05 mM), used at one-tenth and one-fourth of the concentrations given to cell lines, dramatically decreases size (not shown) and number (B90% inhibition) of cytokine-driven myeloid colony-forming cells from CD34 þ BM CML-BC but not CML-CP (B15% reduction) progenitors (n ¼ 3) (Figure 4a ). Marked (B85-95%) apoptosis (Annexin V þ ) was induced by the same drug combination in CD34 þ progenitors isolated from BM of CML-BC (n ¼ 6; Figure 4b , black bars) but not healthy (n ¼ 3) donors in which a 6-day exposure to both drugs resulted in a 40% reduction in viability (Figure 4b, white bars) . A significant but modest (B50% reduction) impairment of CD34 þ CML-BC (n ¼ 3) colony formation was observed when these drugs were used separately (Figure 4a ). This correlated with a 30% decrease in viability of ABT-263-but not PP242-treated CD34 þ BM cells from CML-BC (n ¼ 6) and healthy (n ¼ 3) individuals (Figure 4b) .
Previous studies show that the BM stroma protects CML-BC (cell lines 9 and primary cells 10 ) from TKI-induced cell death. To determine whether PP242 and ABT-263 treatment overcomes microeviromentally induced drug resistance, LAMA84 cells were cultured for 42 h in CM from the TERT þ human mesenchymal stem cell line, while exposed for 24 h to either 1 mM imatinib or the combination 0.1 mM ABT-236 and 0.2 mM PP242. Flow cytometric analysis of Annexin V/Sytox Blue-stained cells showed near complete cell death in LAMA84 cells treated for 24 h with ABT-263 and PP242 regardless of the presence of BM stroma CM (Figure 4c ). As expected, TKI (for example, imatinib)-induced apoptosis was strongly inhibited by culturing LAMA84 cells in hTERT þ stromal cell CM, suggesting that suppression of Bcl-xL/Bcl-2 and TORC1/2 pathways efficiently overcomes extrinsic BM stromal signals conferring resistance of Ph þ leukemic progenitors to TKI-induced apoptosis.
Impaired Bcl-xL expression by hnRNP A1 shRNAs mimics the proapoptotic effects of ABT-263 and potentiates efficacy of PP242 HnRNP A1 expression was found to gradually increase, in a BCR-ABL kinase-dependent manner, in paired CML-CP and -BC BM MNC samples. 37 We found that levels of hnRNP A1 are specifically elevated in the CML-BC cell populations which, as reported, show innate or acquired TKI resistance, 48 have the ability to self-renew 49 and, most likely, represent the origin of the progressing cell clone. 4 In fact, hnRNP A1 expression was increased in CD34 þ /CD38 As hnRNP A1 is a positive post-transcriptional modulator of Bcl-xL expression, 37 we modulated levels of hnRNP A1 with shRNA to better understand the molecular mechanisms by which the Bcl-xL/ Bcl-2 antagonist ABT-263 exerts its pro-apoptotic activity in BCR-ABL þ CML-BC progenitors. Knock down of hnRNP A1 in primary CD34 þ CML-BC BM cells (n ¼ 3) resulted in downregulation of Bcl-xL but not Bcl-2 (Figure 5b, left) and mimicked the effect of ABT-263 when hnRNP A1 shRNA-expressing CD34 þ CML-BC BM cells (n ¼ 3) were exposed to 0.1 mM PP242 (Figure 5b, right) . Annexin V staining revealed shRNA-mediated decreased levels of hnRNP A1 impaired survival of CD34
þ CML-BC progenitors by B60% 6 days after GFP selection compared with vector-transduced progenitors (Figure 5b) . Viability of shRNA-infected cells was further reduced (Pp0.05) upon addition of 0.1 mM PP242 (B20% survival), suggesting that expression of Bcl-xL rather than Bcl-2 is important for survival of CML-BC progenitors and that ABT-263 exerts its proapoptotic activity in CML-BC cells through inhibition of Bcl-xL. As expected, shRNA-mediated suppression of hnRNP A1 expression (B65% inhibition) resulted in downregulation of the hnRNP A1-target suppressor of variegation, enhancer of zeste, and Trithorax (SET), thereby leading to PP2A reactivation 4, 50 and, consequently, downregulation of BCR-ABL1 and its downstream effectors (for example, hnRNP E2 and K) 43, 44 in CD34 þ CML-BC progenitors (Figure 5b ). 
DISCUSSION
The dismal outcome of patients with CML-BC treated with either TKIs or other experimental drugs reflects our lack of a clear understanding of which BCR-ABL kinase-dependent and/or -independent pathways are significantly contributing to disease progression. 2, 4 Among these, several regulators of apoptosis (for example, Bcl-xL) have been proposed to be important for survival of CML-BC progenitors; 51 however, whether their contribution is critical for disease progression in vivo is still unclear. By using a mouse model of CML blastic transformation, 36 we showed that the anti-apoptotic factor Bcl-xL is dispensable for development and maintenance of a CML-CP-like disease in mice but required for transformation into an L-BC-like disorder ( Figures  1 and 2 and Supplementary Figure S1 ). Development of leukemia in the absence of bcl-x expression in vivo was unexpected because of both the dependence of Bcl-xL expression on BCR-ABL1 kinase activity and the numerous in vitro studies suggesting a role for BclxL in BCR-ABL1 kinase-dependent and -independent survival of CML-BC cells and their resistance to pro-apoptotic stimuli. 9, 12, 13 We also showed that genetic and pharmacological (ABT-263) loss of Bcl-xL expression and/or activity did not alter BCR-ABL1 þ stem cell (LSK) number, survival and self-renewal activities while preventing in vivo expansion of more committed progenitors which, like the CML-BC GMPs, 4, 49 represent a secondary CML cell population demonstrating increased BCR-ABL1 expression, survival/proliferation advantage, increased genomic instability and, likely, self-renewal. However, while the L-BC-like disease maintains BCR-ABL1 kinase-dependence in dTg mice, relapse and BCR-ABL kinase-independence are two phenomena commonly observed in TKI-treated CML-BC patients. 36, 38 Furthermore, despite the proposed role for Bcl-2 in disease progression, 46 ,52 expression studies done in CML patients indicate that disease progression does not directly correlate with Bcl-2 levels, 53 suggesting that BclxL, and possibly its negative regulator BAD, may have an important role in both CML-BC development and BCR-ABL1-independent TKI resistance, which is likely induced by microenvironment-generated signals rather than depending on the presence of leukemic cell clone(s) harboring BCR-ABL1 mutations. 9, 10 In support of a significant biological role played by both Bcl-xL and BAD in CML-BC and not CML-CP, we showed that low concentrations of the orally available Bcl-2/Bcl-xL inhibitor ABT-263 (100 nM) exerts a strong and selective cytotoxicity towards CD34 þ CML-BC but not CP or normal progenitors ( Figures 3 and 4) when used in combination with suboptimal concentrations of drugs (for example, 50 nM PP242), which lead to BAD activation ( Figure 3) . Indeed, treatment of both BCR-ABL1 þ cell lines and CD34 þ CML-BC progenitors with combined low doses of ABT-263 and PP242 reduced viability by B90% without having any significant effect on CD34 þ hematopoietic cells from healthy individuals. The antileukemic effect of a combined Bcl-xL/Bcl-2 antagonist (that is, ABT-737 or ABT-263) and PP242 treatment has been previously investigated in cell line models of Burkitt's lymphoma (0.5 mM ABT-737/1.25 mM PP242) and acute T-cell leukemia (T-ALL; 0.01-1 mM ABT-263/0.01-1 mM PP242). 54, 55 However, while the ABT-263/PP242 combination strongly resulted in apoptosis of primary CML-BC cells and cell lines, these drugs had only a modest killing (30% induction of apoptosis) in Burkitt's lymphoma and a very limited synergistic effect in T-ALL cell lines, 54, 55 suggesting that the Bcl-xL/BAD interplay specifically has a crucial role in survival of CML-BC but not all leukemic progenitors. Note that alone, neither ABT-263 nor PP242 had a significant effect on survival of CML-BC progenitors when used at 0.1 and 0.05 mM concentrations, respectively (Figure 4 ), although it has been shown that higher doses of PP242 decreased clonogenic potential of CML-BC cells, 35 most likely through its inhibitory effect on mTORC1/2-Akt1-regulated Mcl-1 expression (Figure 3) . Consistent with our data obtained with 100 nM ABT-263 in both leukemic and normal CD34 þ progenitors, it has been reported 23 that suppression of Bcl-xL/Bcl-2 activities by 100 nM ABT-737 accounts only for 20-30% of apoptosis. Furthermore, low or no sensitivity to the ABT-737/ABT-263 compounds, even if used at concentrations as high as 10 mM, has been reported for Ph þ cell lines and primary CML stem/progenitor cells. 23, 25, 56 The limitation of this drug as a single therapeutic agent in CML-BC is supported by evidence indicating that resistance to its proapoptotic activity is induced in malignancies (for example, CML-BC 9, 12, 13 ) where Bcl-xL and/or Mcl-1 are overexpressed. 23, 57 Given that microenvironment-induced TKI resistance has also been, in part, associated with the ability of extracellular BM soluble factors to increase Mcl-1, Bcl-xL, survivin and mTORC1/2 levels in leukemic progenitors, 9, 58 and that downregulation of Mcl-1 restores sensitivity of leukemic cells to ABT-737, 59, 60 it is likely that a combined ABT-263/PP242 would be more effective than the single-agent approaches. Indeed, we not only provided evidence indicating that PP242 is capable of reducing Mcl-1 levels but also showed that ABT-263/PP242 treatment efficiently (90% induction) promoted apoptosis of CML-BC cells even in the presence of external factors (hTERT þ stromal cell CM) capable of inducing TKI resistance (Figures 3 and 4) . Mechanistically, shRNA-mediated suppression of BAD or hnRNP A1 that, in turn, leads to Bcl-xL but not Bcl-2 downregulation, allowed us to determine that inhibition of Bcl-xL and restoration of BAD activity mostly accounts for the apoptosis induced in CD34
þ CML-BC progenitors by the Bcl-xL/ Bcl2 antagonist ABT-263 and mTORC1/2 inhibitor PP242, respectively ( Figure 5 ). However, it is likely that PP242-induced inhibition of the mTORC1/2-and Akt-mediated survival signals also has a key role in the apoptotic response of leukemic progenitors to the ABT-263/PP242 combination ( Figure 6 ). Additionally, the strong apoptotic effect of the ABT-263/PP242 combination might also depend on interference with other BCR-ABL1 kinase-dependent and -independent survival signals. In fact, co-treatment of ABT-737 with imatinib induced not only a B50% and B25% apoptosis in CML-BC 23, 56 and normal progenitors, 23 respectively, but also restored TKI sensitivity of CD34 þ /CFSE MAX CML-BC and CD34 þ / CD38 À CML-CP stem cell-enriched populations, 23, 56 suggesting that BCR-ABL1-dependent and -independent survival pathways are simultaneously affected.
In conclusion, although we cannot determine whether the combination of ABT-263 with PP242 would be more effective than TKIs in CML-BC therapy, our in vitro data strongly suggest that pharmacological inhibition of Bcl-xL together with activation of its negative regulator BAD has a greater and more profound deleterious effect (90% induction of apoptosis in the presence of external cytokines) on survival of CML-BC progenitors regardless of the drug resistance induced in these cells by BM-generated signals. 9, 10 Finally, it remains unknown whether TKIs with ABT-737/ABT-263 treatment would be sufficient to induce a sustained molecular remission or the B50% surviving drug-resistant CML-BC progenitors would account for relapse. Of clinical interest, our data support the application of an alternative therapeutic protocol in which patients would be initially de-bulked with TKIs to reduce leukemic blast burden and, thereafter, treated with ABT-263 and PP242 to eliminate residual TKI-resistant CML-BC clones. 
